Genprex (LTS:0A8I) ROE % Adjusted to Book Value : -180.56% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Genprex ROE % Adjusted to Book Value?

Genprex's ROE % for the quarter that ended in Dec. 2024 was -1,054.49%. Genprex's PB Ratio for the quarter that ended in Dec. 2024 was 5.84. Genprex's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -180.56%.

Genprex ROE % Adjusted to Book Value Historical Data

The historical data trend for Genprex's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex ROE % Adjusted to Book Value Chart

Genprex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-39.21

-25.85

-112.36

-80.01

Genprex Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-130.01	-476.23	-327.78	-445.28	-180.56

Competitive Comparison of Genprex's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Genprex's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genprex's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Genprex's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Genprex ROE % Adjusted to Book Value Calculation

Genprex's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-467.26%	/	5.84
	=	-80.01%

Genprex's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-1,054.49%	/	5.84
	=	-180.56%

Genprex ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Genprex's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Genprex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (LTS:0A8I) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

GNPX:USA

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Headlines

No Headlines